Multi-gene (multiplex) panels: more genes, more answers — and more uncertainty
A multiplex panel reads many cancer-susceptibility genes from one sample. It finds more carriers than testing BRCA1 and BRCA2 alone, but the rate of uncertain results climbs with every gene added. Here is the evidence behind that trade-off.
What a multi-gene panel actually does
A multiplex (multi-gene) panel sequences a curated set of cancer-predisposition genes in a single assay, rather than testing one gene at a time. Panels range from focused (around 5–11 genes) to broad expanded panels (25–80+ genes). The clinical case is straightforward: many families with a hereditary-cancer pattern carry a pathogenic variant outside BRCA1/BRCA2, and a panel catches those in one pass.
The cost is interpretive, not technical. Adding genes adds signal — but also adds variants of uncertain significance (VUS), rare sequence changes whose effect on cancer risk is not yet known. The PROMPT registry was built precisely to pool these rare findings across institutions so their risk can be characterised over time. This page is an educational explainer, not medical advice — discuss any personal result with a clinician or genetic counsellor.
Example panel genes and associated risk
A representative slice of genes commonly included on hereditary breast/ovarian panels, grouped by penetrance. Risk figures are published ranges, not individual predictions; magnitude depends on the specific variant, family history, and ancestry.
| Gene | Tier | Approx. lifetime breast-cancer risk | Notes |
|---|---|---|---|
BRCA1 | High penetrance | ~65–85% by age 70 | Also elevated ovarian-cancer risk |
BRCA2 | High penetrance | ~45–85% by age 70 | Ovarian, pancreatic, prostate associations |
PALB2 | High penetrance | ~33–58% lifetime | Partner of BRCA2; risk overlaps high-tier genes |
CHEK2 | Moderate penetrance | ~37% lifetime | Common in general population; risk variant-dependent |
ATM | Moderate penetrance | ~20–30% (range 13–33% by age 80) | ~2-fold over baseline; pancreatic association |
Table 1. Selected susceptibility genes — penetrance tier and approximate lifetime breast-cancer risk.
VUS rate rises with panel size
Pooled clinical data show the proportion of patients receiving at least one variant of uncertain significance grows as more genes are sequenced — driven almost entirely by non-BRCA genes. Values are illustrative midpoints from the cited literature.
Two well-characterised genes; low VUS yield
VUS prevalence ~13.8%
VUS prevalence ~31.8%
Up to ~64% in older-patient cohorts
Glossary
Terms that recur whenever panel results are discussed.
- Penetrance
- The probability that a person carrying a pathogenic variant actually develops the associated condition. High-penetrance genes (e.g.
BRCA1) confer large lifetime risks; moderate-penetrance genes (e.g.ATM,CHEK2) confer smaller, often roughly 2-fold, increases. - VUS
- Variant of uncertain significance — a sequence change (e.g.
rs80357906-style identifiers) that cannot yet be classified as benign or pathogenic. It is not an actionable result and should not drive surgery or screening decisions on its own. - ACMG/AMP tiers
- The five-class framework — benign, likely benign, uncertain, likely pathogenic, pathogenic — used to interpret each variant. Moderate-penetrance genes such as
ATMhave needed gene-specific criteria because the standard rules were built around high-penetrance phenotypes. - Multiplex panel
- A single assay sequencing many genes at once, as opposed to sequential single-gene tests.
Common questions about panel size
Is a bigger panel always better?
Not necessarily. Larger panels find more pathogenic carriers (40–50% more than BRCA1/BRCA2 alone), but they also return far more VUS — rising from a few percent on a focused test toward 30% or higher on expanded panels. A VUS is not a diagnosis and can cause anxiety or, worse, prompt unwarranted action. Panel choice should match the clinical question.
What is the difference between high- and moderate-penetrance genes?
High-penetrance genes such as BRCA1, BRCA2 and PALB2 carry large lifetime risks. Moderate-penetrance genes such as CHEK2 and ATM roughly double baseline risk — meaningful, but managed differently. Guidelines (NCCN, ACMG) tailor screening to the specific gene rather than treating every positive the same way.
What should I do if my result is a VUS?
In general, a VUS should not change medical management. Classifications are revisited as evidence accrues — registries like PROMPT exist to pool rare variants so their risk can be resolved. A genetic counsellor can explain whether your variant has been reclassified and what follow-up, if any, is appropriate.
Why does the VUS rate depend on ancestry?
Reference databases historically over-represent people of European ancestry, so individuals of African, Hispanic, or Asian and Pacific Islander background tend to receive more VUS calls — not because they carry more risk, but because fewer of their variants have been characterised. Closing that gap is an active research priority.
- [1]NCI. National Cancer Institute. Genetic Testing for Inherited Cancer Susceptibility Syndromes.↗
- [2]Cleveland Clinic / ConsultQD. Genetic Risk Assessment for Breast Cancer Using Multi-gene Panel Testing.↗
- [3]JCO 2023. Yadav S et al. Contralateral Breast Cancer Risk Among Carriers of Germline Pathogenic Variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2. J Clin Oncol.↗
- [4]WJON 2024. Multi-Gene Panel Testing for Hereditary Cancer Predisposition Among Patients Sixty-Five Years and Above Diagnosed With Breast Cancer.↗
- [5]ACMG 2024. Management of individuals with heterozygous germline pathogenic variants in ATM: an ACMG clinical practice resource. Genetics in Medicine.↗
- [6]ASCO/JCO — PROMPT. Prospective Registry of Multiplex Testing (PROMPT): a web-based platform to assess cancer risk of genetic variants. Robson, Domchek, Couch, Offit.↗
From the genes to the report
Once a panel runs, the hard part is reading what it returns. Continue with how a single high-penetrance gene is tested, then how to interpret the result responsibly.